InTIME II-TIMI 17

OBJECTIVE: To compare the single-bolus fibrinolytic agent lanoteplase (nPA) with accelerated rtPA for the treatment of patients with ST elevation myocardial infarction.

View/Download
_______________________________________________________________________________

  1. Intravenous nPA for the treatment of infarcting myocardial early: InTIME-II, a double blind comparison of single bolus lanoteplase vs. accelerated alteplase for the treatment of patients with acute myocardial infarction. The InTIME-II Investigators. Eur Heart J. 2000; 21: 2005-2013.
    | Abstract | Request Reprints |

  2. Geographic variation among hospitals participating in a world-wide thrombolytic trial: An InTIME-II substudy. Giugliano RP, Llevadot J, Antman EM, McCabe CH, Foxley A, Skene A, Wilcox R, Chew P, Neuhaus K-L, Braunwald E. Eur Heart J 1999;20:519.
    | Request Reprints |

  3. Hospital profiles and clinical outcomes stratified by on-site catheterization availability. An InTIME-II substudy. Llevadot J, Giugliano RP, Antman EM, McCabe CH, Foxley A, Skene A, Wilcox R, Chew P, Neuhaus K-L, Braunwald E. Eur Heart J 1999;20:356.
    | Request Reprints |

  4. Very early risk stratification after thrombolytic therapy with a bedside myoglobin assay and the 12-lead electrocardiogram. De Lemos JA, Antman EM, Giugliano RP, et al. Am Heart J 2000;140:373-8.
    | Abstract | Request Reprints |

  5. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.de Lemos JA, Antman EM, Giugliano RP, et al. Am J Cardiol 2000;86:1235-7, A5
    | Abstract | Request Reprints |
  7. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Morrow DA, Antman EM, Charlesworth A, et al. Circulation 2000;102:2031-7.
    | Abstract | Request Reprints |

  8. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.de Lemos JA, Antman EM, Giugliano RP, et al. Am J Cardiol 2000;86:1235-7, A5
    | Abstract | Request Reprints |

    .
  9. Revascularization practice patterns: a risk-adjusted analysis using the TIMI risk score for STEMI in InTIME-II. Morrow DA, Guigliano RP, Charlesworth A, Cairns R, Cutler SS, de Lemos JA, McCabe CH, Braunwald E. Circulation 2000; 102(Suppl II): II-846.
    | Request Reprints |

  10. Clinical outcome remains poor in diabetics with myocardial infarction despite early fibrinolytic therapy: findings from InTIME-II. Piana RN, Giugliano RP, Coulter SA, deLemos JA, McCabe JA, Antman EM, Skene AM, Neuhaus KL, Braunwald E. J Am Coll Cardiol 2000; 35 (Suppl A): 407A-8A.
    | Request Reprints |

  11. Recurrent ischemia and clinical outcome after thrombolysis for myocardial infarction: observations from InTIME-II. Warnica W, Antman EM, Wilcox R, McCabe C, Neuhaus K, Braunwald E. J Am Coll Cardiol 2000; 35(Suppl A): 386A.
    | Request Reprints |

  12. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality. Giugliano RP, Antman EM, Thompson SL, McCabe CH, Braunwald E.J Am Coll Cardiol 2001;37(Suppl):316A.
    | Request Reprints |

  13. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Giugliano RP, Llevadot J, Wilcox RG, et al. Eur Heart J 2001;22:1702-15.
    | Abstract | Request Reprints |

  14. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage. Giugliano RP, McCabe CH, Antman EM, et al. Am Heart J 2001;141:742-50.
    | Abstract | Request Reprints |

  15. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction. Llevadot J, Giugliano RP, Antman EM, et al. Eur Heart J 2001;22:2104-15.
    | Abstract | Request Reprints |

  16. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Morrow DA, Antman EM, Giugliano RP, et al. Lancet 2001;358:1571-5.
    | Abstract | Request Reprints |

  17. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. Morrow DA, Antman EM, Parsons L, et al. JAMA 2001;286:1356-9.
    | Abstract | Request Reprints |

  18. Prediction of intracranial hemorrhage in the InTIME-II trial. Sloan MA, Giugliano RP, Thompson SL, Antman EM, McCabe CH, Braunwald E. J Am Coll Cardiol 2001; 37 (Suppl A): 372A.
    | Request Reprints |

  19. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Antman EM, Cooper HA, Gibson CM, et al. Eur Heart J 2002;23:928-33.
    | Abstract | Request Reprints |

  20. Usefulness of prodromal unstable angina pectoris in predicting better survival and smaller infarct size in acute myocardial infarction (The InTIME-II Prodromal Symptoms Substudy). Christenson RH, Leino EV, Giugliano RP, Bahr RD. Am J Cardiol 2003;92:598-600.
    | Abstract | Request Reprints |

 

 

Home | Trials | Core Laboratories | Services | Publications | Education | Funding | Contact Us |

© 2009 All Rights Reserved TIMI Study Group